CBD Industry Set to Explode as New Products, Consumers Enter Market

CannabisNewsWire Editorial Coverage: The U.S. Farm Bill that recently passed into law is a game-changer for the CBD space. While it is unknown when nationwide cannabis legalization may occur, incredible opportunities exist right now for CBD-focused companies that can deliver products to the marketplace.

  • Demand is growing for organic CBD products in markets where such products are legal.
  • Youngevity has made a series of strategic acquisitions to help establish the company’s position
  • Companies ready to deliver CBD products to market at scale are in ideal position to capitalize on growing demand.

Passage of the latest U.S. Farm Bill marked a watershed moment for CBD producers in the United States. Not only does the new body of law allow these producers to commercialize existing CBD products, the door is now open for a new generation of research into what CBD can do for consumers. Youngevity International Inc. (NASDAQ: YGYI) (YGYI Profile) is a leading producer of consumer-focused CBD products that is expanding its reach into other areas of the CBD supply chain. It joins companies such as CV Sciences Inc. (OTCQB: CVSI), Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF), GW Pharmaceuticals plc (NASDAQ: GWPH) (OTC: GWPRF), and Curaleaf Holdings Inc. (OTCQX: CURLF) (CSE: CURA), which are all working to commercialize CBD products in both the consumer and pharmaceutical sectors.

To view an infographic of this editorial, click here.

CBD Offers New Opportunities for Bold Thinkers

The market for CBD products is exploding and likely will continue to grow as these products become more available. Because CBD can be made in a laboratory, an increasing amount of synthetically produced CBD has been entering the market. However, many CBD proponents contend that organic CBD (CBD extracted from hemp plants) is superior to synthetic CBD.

Youngevity International Inc. (NASDAQ: YGYI) produces a range of consumer-focused CBD products, but the company is growing its reach via strategic acquisitions. Sourcing organic CBD has been an issue for many manufacturers, which may be why Youngevity recently acquired Khrysos Global — a CBD producer based in Florida.

Following the announcement of this acquisition to the public, YGYI president and CFO Dave Briskie commented, “We set out a plan to create a vertical opportunity in the hemp space. This is a significant step as it relates to the production, cultivation, and extraction of hemp, CBD oil, as well as other CBs (cannabinoids). . . . We proudly welcome Dwayne Dundore, as the President of newly formed Khyrsos (sic) Industries along with his entire and very capable team at Khrysos and INX Labs.”

Dundore was equally enthusiastic about the announcement, saying, “I am really excited to be a YGYI shareholder and part of the Youngevity Family. I look forward to making a meaningful contribution to both the top and bottom line of the company and feel strongly that our capabilities and plans for expansion should create additional value for myself and all shareholders.”

CBD Ready to Take the Market by Storm

Unlike THC, which is a highly psychoactive alkaloid found in cannabis, CBD has a calming effect in most people. In addition, CBD can be legally sold without a prescription and is being integrated into many consumer products.

CBD companies that can create good connections with their client bases should be able to grow into this burgeoning market. Recognizing this, Youngevity has made a series of strategic acquisitions that could help establish the company’s position as a leader in 21st-century cannabis development. The company’s takeover of Khrysos Global netted it a solid supply of organic CBD, as Khrysos has both cannabis cultivation property and facilities to refine CBD oil.

With that backdrop, Youngevity recently launched HempFX to sell its products directly to consumers. For the moment, the company is offering hemp oils. Its product line may increase as additional research and development brings more ideas to market.

A Coffee Door Opener

Youngevity is also ready to bring a CBD-infused coffee to market. Its recent acquisition of Khrysos Global brought CBD-testing laboratories to the company, looking to leave Youngevity in a position to take full advantage of the new U.S. CBD laws. One of the biggest hurdles for manufacturers of CBD products is making sure the products contain a repeatable dose of CBD. Through careful testing, Youngevity has overcome this obstacle in its coffee, which reliably delivers 10mg of CBD in every cup.

The new coffee will be made by Youngevity’s wholly owned subsidiary CLR Roasters. According to the company, the new product will be sold in four flavors and will be available to consumers later this year.

CLR Roasters president Ernesto Aguila commented, “We are extremely pleased with the taste of the product, and the samples that we have provided to a host of retailers have led to strong reviews as well. It is very exciting to bring a new product to market that has so much interest within the coffee beverage category. I have not seen a door opener like this since Javalution Coffee Company created the first fortified coffees.”

Market Viability Looks Strong

CBD has essentially been illegal since modern medicine began. Now that it is legal to produce and distribute CBD in the United States, early movers in the space are setting themselves up for potentially massive profits. Numerous companies are focusing on developing better CBD-infused products, creating new forms of consumer-focused CBD consumables and getting those products to consumers as quickly and easily as possible.

CV Sciences Inc. (OTCQB: CVSI) is working to commercialize CBD products for both consumers and the medical community. Its pharmaceutical division is looking to create a CBD-based medicine that can be approved by the U.S. Food and Drug Administration. Now that CBD is 100 percent legal at a federal level in the United States, the company should be able to make progress on this project. Its consumer division is developing a range of products that can be sold to health food stores or directly to its customers. As CBD use has become more widespread, there is a growing amount of feedback from users to support its continued development.

Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) has built a CBD-focused business with operations in the United States, the United Kingdom, and other countries. Kevin Swadish, the company’s chief revenue officer, commented, “The legalities of hemp-based CBD are becoming more favorable, and consumer awareness of CBD is rapidly rising. As a result, we believe the greatest growth opportunities in the industry, and for Isodiol, lie in the consumer packaged goods marketplace.” The company has built up an operation with more than 200 employees and consultants globally, which demonstrates the interest CBD has generated in recent years.

GW Pharmaceuticals plc (NASDAQ: GWPH) (OTC: GWPRF) developed the first marijuana-derived pharmaceutical to be approved by the FDA. Epidiolex, which contains CBD, was designed to treat Dravet syndrome and was the first drug ever approved to treat this rare form of epilepsy in the U.S. Sales of the drug began last November, and according to recent financial results posted by the company, Epidiolex has garnered substantial interest. Epidiolex sales totaled around $4.7 million in the last quarter, with more than 4,500 new patient enrollment forms during the first two months the drug was available. The positive results from Epidiolex sales were well received, and investors bid the company’s shares higher after they were announced.

Getting CBD products into the hands of consumers is also a focus for savvy companies looking to the future. Curaleaf Holdings Inc. (OTCQX: CURLF) (CSE: CURA) recently announced a distribution deal with CVS Health Corp. Under the new deal, the retail pharmacy and healthcare company will begin selling products infused with the trendy, nonintoxicating hemp component at more than 800 of its stores nationwide. CVS confirmed that it has started selling CBD creams, sprays and lotions in eight states, including California, Illinois, Colorado and Alabama. The products will be sold in store aisles. “We’ve been having dialogue with national retailers for many months now,” said Curaleaf chief executive officer Joseph Lusardi. “We’ve got a number of potentially exciting partnerships in the pipeline.”

Growing hemp and refining it into CBD could become profitable for companies that can do it efficiently, especially if public demand grows faster than production capacity. Youngevity may be picking up on this emerging market dynamic and securing its supplies of organic CBD while the industry is still in its infancy.

For more information on Youngevity, visit Youngevity International, Inc. (NASDAQ: YGYI)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

More Mergers Expected as Cannabis Sector Heads into New Year of Growth

CannabisNewsWire Editorial Coverage: Several years of impressive growth are expected to continue in the cannabis sector in 2019, and companies are making the most of it through mergers and acquisitions.

  • The cannabis industry has seen growth in acquisitions over the past two years.
  • A large part of this comes from the emergence of the hemp/CBD market.
  • Industry commentators expect these trends to continue.

SinglePoint Inc. (OTCQB: SING) (SING Profile) is tapping into this exciting potential through a strategy of well-financed acquisitions and investment in other cannabis companies. PotNetwork Holdings Inc. (OTC: POTN) has built up a series of subsidiaries and is now reaching out to mainstream markets with its products. KushCo Holdings Inc. (OTCQB: KSHB) has recently established new supply arrangements that will increase its already growing profits. Following the legalization of hemp farming, CV Sciences Inc. (OTCQB: CVSI) has become one of the United States’ first certified hemp producers. And The Green Organic Dutchman (OTCQX: TGODF) (TSX: TGOD) (TGOD Profile) is building improved cultivation facilities to meet the demand of cannabis’s growing customer base.

To view an infographic of this editorial, click here.

The Cannabis Merger Boom

Over the past year, the cannabis industry has seen a significant new trend emerge. So far, the industry has mostly been made up of small businesses, but a series of mergers and acquisitions have started to change the layout of the land. The larger, more confident cannabis businesses have started to absorb their smaller competitors, creating businesses with greater efficiency, vertical integration and increased market shares.

This boom in cannabis mergers and acquisitions extends beyond committed cannabis companies. Top-tier businesses have started paying attention to the sector, buying substantial holdings in cannabis companies. Cannabis companies themselves have encouraged this interest, seeking outside help to fuel their growth.

The Merger Market

For companies building a strategy around cannabis acquisitions, such as SinglePoint Inc. (OTCQB: SING), current trends are legitimizing what they already held to be true — that there’s great potential in building larger, more diverse cannabis companies through mergers and acquisitions.

The numbers are clear. Eighty-six cannabis companies in the United States were targeted for mergers and acquisitions in 2017, and that number rose to 140 in 2018. That’s a significant increase two years in a row for an industry that’s previously been driven by small start-ups, and commentators expect the trend to continue. In Canada, recreational legalization has triggered an intensive period of ambitious growth. In the United States, the illegality of transporting cannabis across state lines has discouraged expansion beyond the state level, but companies are starting to overcome that barrier, finding ways to run nationwide businesses in a state-by-state market.

For SinglePoint, this means making moves such as the company’s recent significant investment in TorusMed, an organization working on finding new ways to grow industrial hemp. Hemp is an important subset of the cannabis industry — and one that looks set to expand, thanks to federal legalization of the crop under the 2018 Farm Bill.

The bill allows cultivators to grow hemp for cannabidiol (CBD), an increasingly popular component, without the restrictions placed on other forms of cannabis. SinglePoint’s work with TorusMed is aimed at producing more consistent crops of high-CBD hemp with lower costs because of TorusMed’s greater efficiency. The investment appears to provide an effective way for SinglePoint to gain an advantage in the cannabis sector across the United States and beyond.

SinglePoint’s investment in TorusMed isn’t an isolated example. SinglePoint has built a solid strategy around acquisitions and investment. SinglePoint President Wil Ralston appeared on MoneyTV to discuss the company’s financing options for acquisitions, and in November, SinglePoint announced that it had raised $5 million in fresh funding from its own investors for the explicit purpose of fueling this approach. Thanks to the confidence of the market in the future of cannabis, SinglePoint has had no trouble raising funds or gaining attention for its work.

A Growing Industry

One of the reasons SinglePoint has seen such success in finding funding is the wider growth of the cannabis sector.

In the United States, where SinglePoint is based, cannabis legalization has steadily been spreading on a state level. Thirty-three states have now made the drug legal for medical purposes, while 10 have made recreational cannabis legal. North of the border, Canada has become the first G8 country to legalize cannabis nationally, not only setting an international precedent but also generating interest from American companies. The spread of public health solutions to cannabis use over prohibitory ones has become an international trend, creating a global cannabis market.

Over the past five years, this trend has led in a surprising direction: hemp and CBD. Hemp is a form of cannabis that doesn’t contain THC, the chemical that produces a high in users. Related to that trend, researchers have found growing evidence that CBD, a nonpsychoactive ingredient found in all strains of cannabis, may be beneficial for health and well-being.

This promising research has led to a surge in hemp cultivation and even the legalization of hemp farming in the United States, a move that is expected to provide a lifeline for many struggling farmers. Hemp cultivation is an increasingly large portion of the cannabis market, and one that the deal with TorusMed will help SinglePoint access.

Based on both this shift for hemp and wider trends, commentators are predicting even greater growth in 2019 and beyond; one report has calculated that the industry will be worth $146.4 billion by 2025. Even half that growth would provide a huge opportunity for companies such as SinglePoint, and if the industry actually reaches that figure, current players could be big winners.

Positioning for Advantage

It is in this context that SinglePoint, a company whose other work lies in the tech sector, has made the move to expand its position in cannabis. Through its SingleSeed subsidiary, SinglePoint has become a distributor of hemp-derived CBD products at a critical moment.

“It seems like two years ago I started to hear a little bit about CBD and what it was doing for people,” said SinglePoint CEO Greg Lambrecht. “Momentum has really been building for CBD. People are using it for a variety of things. As CBD becomes legal, you’re going to see this product sold in more traditional stores like Walgreens and 7-Eleven. We’re really excited about our online presence, but we’re also very focused on putting this product into retail too.”

The cannabis market has already been seeing steady growth. The legalization of hemp is likely to continue this promising trend. Companies such as SinglePoint that have raised funding and established a foothold in the hemp sector appear to be well positioned to take advantage of that change.

Lining Up for Growth

Of course, It’s not just a matter of making mergers and acquisitions, it’s making the right ones. Several other companies join SinglePoint in making those sound decisions. Among the companies making significant mergers and acquisitions in cannabis are holding companies such as PotNetwork Holdings Inc. (OTC: POTN). PotNetwork’s subsidiaries cover various parts of the cannabis industry, including production, sales and support; its subsidiaries include Diamond CBD Inc., which produces a line of CBD-based oils, creams and edibles.

Like SinglePoint, KushCo Holdings Inc. (OTCQB: KSHB) has entered the cannabis sector from elsewhere through an interest in providing other services to cannabis companies. In KushCo’s case, this was packaging solutions, the sort of unglamorous but important service that any industry needs. KushCo has since expanded its work in the sector, creating a one-stop shop for cannabis products. This approach paved the way for KushCo to secure new long-term supply arrangements with three large companies, agreements expected to be worth $75 million. Having already seen its quarterly revenues rise 186 percent on the same period last year, 2019 is off to a strong start for KushCo.

CV Sciences Inc. (OTCQB: CVSI) has a business rooted in the fundamentals of the cannabis market, with two distinct business segments: research and development, and consumer products. Following the recent founding of the U.S. Hemp Authority certification program, CV Sciences has become one of the country’s first certified hemp manufacturers. This certification provides CV Science customers assurance about the quality and safety of the company’s products, including verifying that its products are made entirely from hemp and not from other cannabis strains.

The Green Organic Dutchman (OTCQX: TGODF) (TSX: TGOD) produces organic, sustainably grown cannabis, catering to the substantial part of the cannabis market concerned with the environment and ethical farming. The company is building two new growing facilities and has been looking for ways to improve its designs as it builds. Recent improvements will increase production capacity from 156,000kg of cannabis to 202,500kg.

While improvements in technology, techniques and certification are helping companies tap into the growing cannabis sector, mergers and acquisitions are also allowing companies to access all of these while increasing their market share. Those who make the right moves now could benefit from dramatic growth over the next few years.

For more information on SinglePoint, visit SinglePoint Inc. (OTCQB: SING)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Departure of US AG and Democratic House Control Improve Prospects for Hemp Industry

CannabisNewsWire Editorial Coverage: Recent changes in Washington, D.C., are good news for the U.S. hemp industry.

  • The recent departure of Jeff Sessions from the Attorney General’s Office may make it easier for states to enforce their own laws in relation to cannabis and hemp legalization.
  • The Democratic majority in the House may ease the passage of the delayed Farm Bill.
  • These changes could improve the prospects for hemp and cannabis producers.

Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) is a pioneer in the hemp industry, with trial cultivation operations under way in Washington and a range of hemp-derived products on the market. Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) (CSE: CWEB) is also focused on hemp-derived cannabidiol (CBD) products and recently raised its profile through TV coverage. Even before the prospect of reform, CV Sciences, Inc. (OTCQB: CVSI) was seeing record profits this year and increased its profile by becoming a sponsor for the Hemp Industry Association’s 25th anniversary conference. Isodiol International, Inc. (CSE: ISOL) (OTCQB: ISOLF) is benefiting from changes not just in the United States but in Mexico, where new regulations will support its sale of diverse CBD products. The first publicly traded U.S. cannabis company, Medical Marijuana, Inc. (OTC: MJNA) is also seeing growth, with record sales and a continuing high profile.

To view an infographic of this editorial, click here.

A United Group within a Divided Nation

This November’s Congressional elections have been some of the most divisive in U.S. history. Bitterly fought campaigns have culminated in knife-edge results, featuring recounts to settle tiny vote margins amid loud accusations of cheating from both sides.

While the election results and their aftermath have been mixed for both Democrats and Republicans, they have been overwhelmingly positive for one group — hemp producers. A Democratic majority in the House of Representatives may finally bring an end to months of bickering over this year’s Farm Bill renewal, leading to the expected federal legalization of hemp farming in the process. And the forced resignation of U.S. Attorney General Jeff Sessions, which President Donald Trump pushed once the elections were over, has removed one of the biggest stumbling blocks the industry faced.

How Sessions’ Departure Affects Hemp

The resignation of Jeff Sessions was welcomed with relief by companies in the hemp sector, including Marijuana Company of America Inc. (OTC: MCOA), just as his arrival was greeted with disappointment two years before.

During his election campaign, Trump had supported medical cannabis and states’ rights to legalize their own industries. This was good news for hemp companies, which expected to function as the primary producers of medical cannabis.

Hemp, which does not get users high and is useful for a variety of purposes, was banned by the sweeping laws of drug prohibition decades ago. Recent state-level reforms have allowed the establishment of projects such as MCOA’s hemp project in Scio, Ore, in conjunction with their joint venture partner Global Hemp Group Inc. But tension has existed for years between state-level legalization and the continuing federal prohibition on all forms of cannabis. Trump’s offer of reform appeared to be a solution.

Then Sessions came into office. As the government’s top law enforcement officer, he had the power to clamp down on all things cannabis related. And as a vociferous opponent of cannabis, that was exactly what he promised to do.

Though Sessions was not able to launch a new escalation of the war on drugs, his stance on the subject frustrated cannabis proponents. Even as brands such as MCOA’s hempSMART brought a state-legalized flood of hemp-derived products to the health and wellness markets, Sessions’ presence threatened to stifle the fast-growing industry.

However, the cannabis trade and surrounding industries continued to grow despite Sessions’ presence. MCOA is a shining example of an industry-savvy company that has recognized opportunities for growth and development in an industry that reached an estimated value of $9 billion in 2017 and is expected to reach over $47 billion by 2027. The company developed a distinct hemp derived CBD brand — hempSMART™ — and established high yielding hemp cultivation farming projects in the United States and Canada while also investing in Moneytrac Technology, a business providing financial and support services for the cannabis industry.

However, federal restrictions have created uncertainty for companies. By this fall, the White House was hinting at taking a more liberal stance. While this could be seen as a political ploy to balance Sessions’ presence in the minds of cynical cannabis-conscious voters, it also hinted at divisions within the government. It’s hardly surprising with a populist president like Trump. With 64 percent of Americans supporting legalization of cannabis and 74 percent supporting states’ rights to legalize, Sessions was up against the popular view on a widely discussed issue. Though both his appointment and his departure were driven by other factors, his absence opens the way for cannabis reform. And in fact, cannabis companies’ stocks initially rose when the news was announced.

But Sessions’ departure wasn’t the biggest issue for hemp companies such as MCOA. These companies are also closely watching what is happening in the House.

Passing the Farm Bill

The 2018 Farm Bill is one of the most important pieces of legislation the hemp industry has ever seen. A wide-ranging bill covering U.S. agricultural and food policy, it includes provisions that would legalize the large-scale cultivation of industrial hemp.

Under the previous Farm Bill of 2014, such cultivation became legal on a limited scale for purposes of research and trial crops. This led to hemp crop development, such as the cultivation harvested by MCOA this fall at its Oregon site, but not wide-scale production.

The hemp provisions in the 2018 bill are set to change that. Given their potential to offer a profitable new crop for struggling farmers in Republican-held districts, the provisions have gained cross-party support and ensured a place in the bill.

Unfortunately, other provisions have been more controversial. Arguments over how to allocate federal food assistance and how to deal with illegal immigration stalled the bill earlier in the year, and arguments over who will benefit most from the funds have prevented compromise in the months that followed. The future of hemp companies such as MCOA has been in limbo thanks to issues that have nothing to do with hemp.

With the Democrats about to gain control of the House, that appears likely to  change. The biggest hurdle to passing the bill is House Republicans’ desire to set tougher controls for allocating food stamps. But neither Democrats nor Senate Republicans favor these strict rules, so a Democratic majority in the House and the Republican-majority Senate could break the impasse and pass a bill. This has also given Republicans more incentive to pass the bill while they still have power to shape its outcome in the House.

Greater Opportunities for Cannabis Companies

This change is great news for MCOA. As an industrial hemp company, its operations have so far been limited by the provisions of the 2014 Farm Bill and legalization in specific states. The legalization of hemp will allow it to expand its existing cultivation, set up new operations and more easily sell its products into markets across the country.

Plenty of hemp and cannabis companies across the United States will be seizing opportunities created if federal prohibition ends. Many of these companies, such as Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) (CSE: CWEB), are focused on products using CBD. Its widespread use in health and wellness products has propelled these companies into the limelight, with Charlotte’s Web CEO Hess Moallem appearing on CNBC to talk about the growth of CBD and cannabis businesses in the country.

Politicians’ willingness to change their stance on hemp is unsurprising given the growing momentum behind the industry. The Hemp Industry Association is throwing its 25th anniversary convention this year. The milestone event, sponsored by CV Sciences, Inc. (OTCQB: CVSI), marks two-and-a-half decades of revival for a once-powerful industry. The sponsorship opportunity has been hugely beneficial for CV Sciences, which saw record sales and gross profits in the third quarter of 2018.

Isodiol International, Inc. (CSE: ISOL) (OTCQB: ISOLF) is another company focusing on CBD. Its products cover a wide spectrum of uses, including sleep aid, pain management and skin needs. While the political changes in the United States appear positive for Isodiol, the company has also been closely following events in Mexico, where it has distribution agreements with several companies specializing in pharmaceuticals. At the end of October, Mexican authorities published new regulations covering CBD products. These allow hemp to be used in cosmetics, food supplements and herbal products, as well as in medicines. Based on these changes and its established agreements, Isodiol expects to start sales in Mexico in early 2019.

Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, continues to go from strength to strength. Its subsidiaries have been exhibiting at events across America this year as it continues to develop its profile. Like CV Sciences, it has recently seen record sales as the cannabis and CBD markets grow across North America and beyond.

The hemp industry is growing around the world but, with change in the cards in Washington, America appears set to stay at the forefront of the industry.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Growing Cannabis Industry Creates Space for New Strategies

CannabisNewsWire Editorial Coverage: As the cannabis industry continues to grow, companies are using a variety of strategies to secure their places within the sector.

  • The cannabis sector, currently worth over $9 billion in North America, is expected to hit $57 billion globally by 2027.
  • This growth is being fueled by changes in the legal climate and a range of business strategies.
  • These strategies range from R&D focus to M&A, vertically integrating supply channels in the process.

Youngevity International, Inc. (NASDAQ: YGYI) (YGYI Profile), a relative newcomer to the sector, is bringing its vertically integrated strategy from the coffee market to cannabis. GW Pharmaceuticals Plc (NASDAQ: GWPH) is focused on the medical market, developing prescription medicines among other products. Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) (CSE: CWEB) is focused on reaching more retail outlets, pushing its CBD products out through a growing number of channels. CV Sciences, Inc. (OTCQB: CVSI) is primarily research oriented but is also raising its profile through sponsorship of a hemp industry conference. In Canada, Aurora Cannabis, Inc. (NYSE: ACB) (TSX: ACB) is making use of recent changes by establishing a range of new supply agreements.

To view an infographic of this editorial, click here.

A Changing Business

This year has seen huge developments for the cannabis industry in North America. In Canada, recreational cannabis became legal in the middle of October, after a year of political debate and commercial preparation. South of the border, pressure mounted for reform of federal laws to support states making their own choices, with 64 percent of Americans now saying that they favor legalization. While political maneuvering ahead of the midterm elections delayed efforts to legalize industrial hemp through the 2018 Farm Bill, voters supported the legalization of medical cannabis in Missouri and Utah and of recreational cannabis in Michigan. With cannabis now legal for medical use in 33 states and for recreational use in 10, prohibition is clearly on its last legs.

This wave of change is leading to staggering growth in the cannabis industry. Companies are seeing dramatic rises in revenue as new markets open up, new products are created and new customers cast off tradition to give cannabis a go. This is creating a new space for cannabis companies to work in, where new strategies are being tested alongside new products.

Cannabis Market Keeps Growing

For companies such as Youngevity International, Inc. (NASDAQ: YGYI) that have a significant investment in cannabis, the past few years have been promising ones. The cannabis market has steadily grown as popular sentiment-driven legalization has opened the way for companies to thrive, which in turn has strengthened their campaigns for further legalization. The success of first medical and then recreational legalization in many states and Canada has reassured others that this is a safe path to follow, creating a North American industry that was worth over $9 billion in 2017, according to a Forbes report. That value is forecast to keep rising, with a predicted value of $47.3 billion by 2027.

With notable exceptions such as Uruguay and Israel, the rest of the world has been slower to follow, but that too is changing. Germany permitted the sale of medical cannabis through pharmacies in 2017. Even Britain, one of Europe’s most conservative countries, opened the door to doctors prescribing cannabis products this year after a high-profile campaign by the mother of an epileptic child. Taken all together, the global market is expected to be worth $57 billion by 2027, according to the Forbes report.

A significant part of that industry is made up of cannabidiol (CBD) products. Derived from both marijuana and industrial hemp, CBD is used in health and wellness products such as Youngevity’s Hemp FX™ range. Though some industry predictions may be unreasonably optimistic, performance indicates that CBD products are increasingly popular and are expected to give a significant boost to cannabis businesses. With Congress expected to legalize widespread hemp cultivation as part of the current Farm Bill, the supply of CBD has the potential to soar.

Developing New Strategies

In the early days of the cannabis industry, corporate strategy was simple. Produce the best cannabis possible, market it within the limited options regulations allowed, and soak up the demand from customers. Now the industry is a more diverse one, from focused pharmaceutical brands to the likes of Youngevity, which combines an interest in CBD with other lifestyle products. Strategies have evolved to match the changing market.

One common path has been that of mergers and acquisitions. In a market full of small businesses, there’s plenty of potential for the big movers to swallow up competitors. This has really taken off in 2018, a year that saw 145 mergers and acquisitions during its first six months, compared with 79 M&As in the first half of 2017.

Investment by and in cannabis companies has also increased. From Sugarmade’s investment of a million dollars in Hempistry to Constellation Brand’s decision to pump billions into Canopy Growth, companies are investing in each other to profit from different parts of the market or to easily enter it for the first time.

For others, product diversification is a common way forward. As the market grows, so does the ingenuity of the companies involved. R&D departments are producing an increasingly wide range of products, whether strains of cannabis or derivatives using CBD. Youngevity has recently added sleep and hydration products to its existing range, as the company finds more uses for CBD and more corners of the market to expand into. The spread of legalization is making it easier for companies to carry out this R&D work, leading to ongoing acceleration in the number of products coming out.

Vertical Integration

While some companies are focusing on horizontal integration, absorbing potential competitors in the same part of the cannabis business, others are looking at vertical integration.

This is the approach taken by Youngevity, with a strategy it refers to as “field to finish.” This is an adaptation of the “field-to-cup” strategy the company takes with coffee, seeking to control the whole supply chain, from the cultivation of beans through to the moment the coffee is delivered to the customer. Except that this product is cannabis instead of coffee.

The field-to-finish strategy offers many advantages for a company that can achieve it. By controlling cultivation, processing and distribution, it can ensure high-quality standards, an important part of Youngevity’s lifestyle brand. It can also benefit from the efficiencies and improved communication that come with an integrated supply chain. Many of the blockages that introduce inefficiencies are more easily removed in a system such as this, leading to a leaner, more cost-effective operation.

Youngevity has only recently entered the CBD market, but the company has grand plans. “We firmly believe in plant-based nutrition, and hemp (CBD) oil perfectly complements our product development philosophy,” said Steve Wallach, the company’s CEO. “Entering this market, which is growing almost exponentially, also should offer a tremendous advantage to our many distributors around the world.”

As Wallach has repeatedly made clear, the products so far released are only the beginning for Youngevity.

Players Big and Small

With the market going through dramatic changes, both large and small companies are making significant moves to expand their slice of the pie.

GW Pharmaceuticals Plc (NASDAQ: GWPH) has built a strategy strongly oriented towards the medical market. This includes not just selling strains of cannabis but creating other medicines based on it. The company has created the first plant-derived cannabinoid medicine to gain U.S Food and Drug Administration approval, getting GW’s products into the prescription drug market across the United States. By creating new and valuable medicines, it is creating a place as a prestigious innovator with customers’ wellbeing at its heart.

Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) (CSE: CWEB) is catering to the broader health and wellness market with its CBD-based products. As mainstream acceptance of CBD grows, the company is expanding into a wider range of stores and has now reached 3,000 outlets.

Like GW, CV Sciences, Inc. (OTCQB: CVSI) has built its business around research, using its expertise to create new products and to sell its services to consumers. CV Sciences was the first hemp CBD nutraceutical company whose products were certified Generally Recognized as Safe (GRAS) by the FDA, helping improve the image of both the products and the cannabis market. The company is further raising its profile within the industry as a sponsor of HIACON 2018, the Hemp Industries Association’s 25th anniversary convention.

For Canadian companies such as Aurora Cannabis, Inc. (NYSE: ACB) (TSX: ACB), recreational legalization has opened up a whole new market that presents new opportunities and new challenges. With the market regulated province by province, companies have to set up supply agreements to cover different regions. Aurora has been busily setting up these agreements, giving it a wide distribution network over an important new market.

The expansion of the cannabis market has led to a range of strategies, from acquisitions and product development to opening up new distribution channels, leading to growth for a diversity of different companies. The next few years will show which strategies work best.

For more information on Youngevity, visit Youngevity International, Inc. (NASDAQ: YGYI)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Industrial Hemp Floodgates Open as CBD Demand Grows

CannabisNewsWire Editorial Coverage: The growing popularity of cannabidiol (CBD), a powerful but nonpsychoactive cannabinoid found in plants of the cannabis family such as industrial hemp, has a lot to do with consumer experience roundly validating the increasingly body of scientific evidence for CBD’s therapeutic value.

  • CBD demand is increasing rapidly as consumers run ahead of the studies.
  • Branding is key to capturing market share while formulation quality drives consumer loyalty.
  • The global potential for the CBD market is immense and largely untapped.

Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) has taken several key steps to set itself up as a power player in the burgeoning CBD space, acting as a cultivation site landlord while also developing revolutionary products containing proprietary CBD compounds via its wholly owned subsidiary, hempSMART. CV Sciences Inc. (OTCQB: CVSI) just introduced PlusCBD Oil™ Gummies at the Natural Product Expo East 2018. Los Angeles-based MedMen (CSE: MMEN) (OTCQX: MMNFF) just signed a $33 million deal to acquire Kannaboost Technology Inc. and CSI Solutions LLC, collectively known as Level Up, an Arizona-based vertically integrated marijuana firm. OrganiGram (TSX.V: OGI) (OTCQX: OGRMF) has just has signed a supply agreement with BC Liquor Distribution Branch, the sole, wholesale distributor of nonmedical cannabis for British Canada. And symbolic of its presence in the cannabis market, Aphria (NYSE: APHA) (TSX: APH) debuted on the New York Stock Exchange last week.

To view an infographic of this editorial, click here.

CBD Already Hot and Getting Hotter

No doubt about it, the CBD market is hot right now. With analyst projections ranging from $2.1 billion to $3 billion within the next three to four years, historic change in the form of a 2018 U.S. Farm Bill that could make CBD and industrial hemp legal nationwide might send the market into hyperdrive.

Diverse Approach Focused on Legal Market

Marijuana Company of America Inc. (OTC: MCOA) has constructed a business model around the immense potential of the industrial hemp-based CBD market and just recently applied for an uplisting to the OTCQB in conjunction with an S-1 filing and anticipated access to a $10 million line of equity financing. The company also tapped former Price Waterhouse and Deloitte & Touche man Jesus Quintero for its CFO job, where his extensive public company reporting and SEC/SOX compliance experience should help expedite matters handily.

The success of the company’s hempSMART line comes from its innovative products, such as HempSMART Brain, a unique formulation of Ayurvedic herbs and botanical compounds with premium CBD designed to enhance brain function. The company’s success also stems from its affiliate marketing program, which allows people to earn income via commissions and bonuses, assisted by a sophisticated networking architecture that was engineered to maximize customer loyalty and market penetration.

Global Potential, Next Level Moves

MCOA has even tapped 35-year direct sales industry veteran Ian Harvey to spearhead hempSMART’s upcoming international product launch starting in Europe at the outset of 2019. As the company’s global sales director, Harvey will seek to deliver the same kind of success with the hempSMART network marketing program as was demonstrated throughout his career in the direct sales industry.

Recently the first of many regional events to be held across the country took place, and the hempSMART South West Regional Event showcases how quickly MCOA has built up its CBD product brand and leveraged its advanced affiliate marketing platform to harness the might of the $189.6 billion direct sales industry. While the company is busy breaking new ground at the forefront of direct sales and CBD, MCOA continues to advance its property interests as well and is focused on leasing turnkey facilities to sector operators in appropriate states and jurisdictions. The latest news from the company’s CBD hemp farming joint venture in New Brunswick, Canada, with Global Hemp Group Inc. demonstrated the ingenuity of MCOA’s farming group. An OXBO bean harvester was used at the New Brunswick project to maximize target yields of the parts of the plant with the highest CBD concentrations, despite unusually difficult crop conditions created by this year’s drought.

Just the Beginning of the Property Leasing Ladder

At the partnership’s Covered Bridge Acres joint venture in Scio, Oregon, work is proceeding apace of expectations. The facility will comprise when completed, some 19,000 square feet of greenhouses for year-round production, paired up with traditional outdoor orchard-style cultivation on the remaining square footage of the 109-acre site. MCOA plans to continue to expand its property footprint in both the United States and Canada as the overall cannabis industry heats up. The company may hold an ace up its sleeve in the form of a close working relationship with British Columbia-based Global Hemp Group. Both companies share a common vision about the disruptive potential of industrial hemp, particularly as evinced by the growing popularity of CBD.

And while many in the mainstream media may still be skeptical about what consumers seem to be discovering firsthand about CBD’s health benefits, a growing body of scientific data appears to back up popular sentiment. Research regarding the ability of cannabinoids such as CBD to regulate homeostasis by impacting the body’s endocannabinoid receptors found throughout nearly every tissue system suggests that consumers are not just experiencing some kind of placebo effect.

Two-Pronged Solution to Soaring Demand

MCOA has put together a noteworthy approach to the overall space, emphasizing immediate access to legal areas of the market. On one hand, Marijuana Company of America has a dynamic affiliate marketing program to promote and sell its legal hemp-based consumer products. In addition, the company has put together a growing property-based presence that looks to increasingly benefit its hempSMART brand’s performance metrics. CBD continues to be costly to produce, and the demand for cultivation sites will likely continue to increase proportionally.

A preeminent supplier and manufacturer of hemp-derived phytocannabinoids, CV Sciences Inc. (OTCQB: CVSI) added to its leading brand, PlusCBD Oil™, with the release of its gummy product. CV Sciences operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products.

By acquiring control of Level Up, MedMen (CSE: MMEN) (OTCQX: MMNFF) gains access to two vertically integrated operations in Arizona, which include retail locations in Scottsdale and Tempe, as well as 25,000 square feet of cultivation and production capacity in Tempe and Phoenix, and a stake in the top-selling K.I.N.D. Concentrates (“K.I.N.D.”) brand, which is currently distributed in more than 90 percent of Arizona dispensaries. The acquisition strengthens MedMen’s presence in one of the top cannabis markets in the United States.

A leading licensed producer of cannabis for the medical and adult-use recreational markets, OrganiGram (TSX.V: OGI) (OTCQX: OGRMF) has now secured cannabis distribution agreements in eight of ten provinces in Canada. Organigram also recently signed an agreement with to acquire 8,333 common shares of Alpha-Cannabis Germany, representing a 25% stake in ACG’s capital. ACG has been preparing the development and production of further cannabis-based products for the swiftly growing German and European markets.

In addition to uplisting on the NYSE, Aphria (NYSE: APHA) (TSX: APH) recently closed acquisitions of assets in Latin America and the Caribbean from Scythian Bioscences. As a result of the transaction, Aphria has solidified an important foothold in Latin America and the Caribbean by acquiring industry-leading cannabis-related companies in Colombia, Argentina and Jamaica as well as a right of first offer and refusal to a majority interest in a Brazilian entity seeking a cannabis cultivation and sales license.

CBD is quickly establishing itself as the darling of the booming cannabis industry. Investors will want to keep a close eye on companies such as MCOA that are able to operate within the sizeable, already-legal portions of the overall cannabis market and that have a specific emphasis on products containing CBD derived from industrial hemp. However, the entire cannabinoid market is worth examining in greater detail, while those companies with unique advantages deserve special attention, as they could be tomorrow’s brightest stars and richest buyouts.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Something for Everyone: Baby Boomers Signify Shift in the Cannabis Market

CannabisNewsWire Editorial Coverage: Since they came onto the scene after World War II, baby boomers have heavily impacted the world around them, and their influence is being felt now in the emerging cannabis market.

  • A recent survey has shown a significant increase in cannabinoid-derived product consumption in the United States, most notably among baby boomers.
  • With a combination of disposable income, health issues and liberal attitudes towards drugs, baby boomers represent a natural market for cannabis companies.
  • This trend also signifies wider growth and diversification of products and customers in the industry.

Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is tapping into this growing market through the production of industrial hemp and the marketing of a wide range of CBD wellness products. Having started out as a medical cannabis company, Organigram Holdings, Inc. (OTC: OGRMF) is adjusting to shifting markets by appealing to recreational consumers while showing loyalty to its existing customer base. A focus on research provides CV Sciences, Inc. (OTC: CVSI) with a growing range of products and the credibility to appeal to health-conscious cannabis consumers. Global innovator and market leader Isodiol International, Inc. (OTC: ISOLF) recently received approval for its cannabidiol (CBD) to be designated as an active pharmaceutical ingredient. And Cannabis Strategic Ventures (OTC: NUGS) just launched a new line of CBD-based luxury skin, hair and body products.

To view an infographic of this editorial, click here.

The Changing Face of Cannabis

It’s hardly surprising to see that baby boomers are an important part of the cannabis and hemp markets. The generation that saw marijuana gain counter-culture popularity in the ‘60s and ‘70s is also a generation with considerable disposable income. As they head into retirement and old age, many baby boomers are looking for ways to enjoy their wealth, as well as ways to manage physical ailments. The growth of both the medical and the recreational cannabis sectors in North America means that this product can cater to both desires.

The growth in cannabinoid consumption by baby boomers is just part of the expansion of the cannabis market. Given the chance to openly research plant and products, manufacturers are vastly increasing the potential of cannabis. Improved strains improve the performance and profitability of the drug, while derivative products and support services turn what was essentially a single product into a whole sector.

Baby Boomers and Cannabis Consumption

For companies such as Marijuana Company of America (OTC: MCOA), baby boomers are an increasingly important market sector. A recent survey of nearly 18,000 adult Americans found that cannabis is becoming increasingly popular among the older generation. The number of cannabis users in the United States has nearly doubled over the past decade, despite it still being illegal in several states and only available for medical use in most. Around 9 percent of those aged 50 to 64 had used cannabis at some point in the year preceding the survey. Among those aged 65 and above, the figure was 3 percent. And while those numbers may not seem impressive, they are steadily growing and represent an increasingly large market for MCOA and its competitors to tap into.

What’s causing this growth in older cannabis users?

Shifting attitudes are clearly a factor. Many baby boomers came of age in the ‘60s and ‘70s, when the hippy movement raised the public profile and popularity of cannabis. They were therefore raised with marijuana as a feature of popular culture, even if they personally didn’t indulge in it. More recently, a shift away from the criminalizing policies of the 1980s towards a more liberal view has started to change attitudes across the generations.

Growing availability is a factor as well. The legalization of medical cannabis in many states has made the drug accessible in ways that it wasn’t before. Given the prevalence of chronic pains and ongoing ailments among those aged 60 and over, it’s relatively easy for seniors in medical cannabis states to get a prescription. And in the states where it’s legal for recreational purposes, the only bar to use is the social attitude of the consumer.

Having grown up during an economic boom and an era with greater government support, baby boomers have emerged with the wealth to enjoy their hobbies in retirement. And for many, cannabis is now one of those hobbies.

Something for Everyone

Baby boomers are just one part of recent growth in the cannabinoid product market. It’s a pattern of growth driven in part by the increasing diversity of cannabis products, sold through separate but interconnected markets.

The first to emerge was the medical cannabis sector. This has grown from a small niche to an important part of the North America market, with cannabis and hemp now legal in parts of the United States and Canada. Millions of people use cannabinoid-based products regularly to help manage chronic pain and treat other ailments, leading to growing recognition that the legal definition of cannabis as having no medical use was both absurd and unscientific.

Medical cannabis has been followed in recent years by the legalization of recreational cannabis. Nine U.S. states and the District of Columbia have taken this step. Canada is following suit on a national level, with legalization coming this October. Strains of cannabis and brands of products aimed at recreational consumers are emerging to cater to a different market from the medical one.

Alongside these products are others related to or derived from other cannabinoids, such as CBD. Industrial hemp, which produces CBD in large quantities, is grown by companies including MCOA, who has the potential to capture a piece of what is projected by The Brightfield Group to be a $22 billion market by 2022. Following trials over the past few years, the cultivation of industrial hemp looks set to become legal across the United States with the upcoming passage of the 2018 Farm Bill.

A wide range of products have been produced using active compounds from hemp. Oils and pills derived from cannabidiol oil (CBD) are increasingly popular in the health and wellness markets, finding their place on the shelves of wholefood shops.

Catering to Varied Needs

One of the reasons for the success of cannabis companies is their ability to manufacture and distribute CBD-related products for vastly different purposes. MCOA’s hempSMART™ product line shows how these companies build up a range of distinct but related products. hempSMART makes use of cannabidiol (CBD), a non-psychoactive chemical found in cannabis and widely used in health and wellness products.

HempSMART Pain and hempSMART Pain Cream use CBD for one of cannabis’s most widely recognized uses — pain management in relation to minor physical activity. It’s why cannabis had grown so popular and part of why its derivatives are also proving so popular with a variety of different age groups.

HempSMART Brain, on the other hand, is designed to improve clarity, concentration and alertness. HempSMART Face has found a way to use CBD in a moisturizer that moisturizes and replenishes the skin cells on your face. And hempSMART Pet Drops let people share the benefits of CBD with their animal companions. It’s a level of variety that may allow MCOA to get its products into many niches, increasing brand awareness as well as sales.

By creating a wide range of products, cannabis companies are catering to a growing number of markets. By helping with issues such as alertness and pain management, they’re ensuring their relevance to that crucial baby boomer market.

Expanding the Range of Cannabis Products

That sort of varied approach to cannabis is leading to growth for Organigram Holdings, Inc. (OTC: OGRMF). Once a medical cannabis company, Organigram still has a strong focus on that market and is showing its commitment to patients by covering the cost of excise tax on their cannabis. But it’s also expanding into the recreational market, contributing one of its award-winning flowers to the world’s first recreational cannabis variety kit. Creating products such as variety kits and gift sets turns cannabis into more of a luxury consumer product, one to be purchased for special occasions.

CV Sciences, Inc. (OTC: CVSI) is strongly focused on the research side of cannabis, using this as both a source of new products and a way of validating its work to consumers. It’s the sort of work that adds credibility to arguments that cannabis is safe and useful for consumers.

Isodiol International, Inc. (OTC: ISOLF) is a market leader in pharmaceutical-grade pure, natural CBD and an industry leader in the manufacturing and development of CBD consumer products. The company’s line of consumable and topical skin care products features 99 percent-plus pure, natural isolated CBD, micro-encapsulations, and nano-technology for the highest quality products.

Cannabis Strategic Ventures (OTC: NUGS) is marrying cannabis science with an increasing global demand for luxury personal care products in LYXR, its newest product line. LYXR products are developed from a line of hemp-derived phytocannabinoids combined with other natural ingredients that provide high-performing skin, hair and body topical solutions. LYXR’s inaugural product will be a face mask designed to provide hydrating and anti-aging/age prevention benefits. The LYXR product line will eventually include skin, hair and body products.

The cannabis market is seeing huge growth in the variety of both products and customers. With baby boomers increasingly enjoying cannabis into retirement, marijuana appears to be well on its way to entering the mainstream.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

The CBD Bonanza on the Horizon

CannabisNewsWire Editorial Coverage: Leveraging ever-expanding scientific evidence of the therapeutic efficacy of CBD (cannabidiol), specialty biotechnology companies are creating novel new formulations of the chemical compound to capitalize on the titanic growth expected in the cannabis-derived pharmaceutical and nutraceutical markets.

Cannabinoids have been used for medicinal purposes for millennia, but it wasn’t until the discovery of the human endocannabinoid system in the 1990s that scientists began to comprehend their importance in healing and homeostasis. The identification of human cannabinoid receptors opened the floodgates to new cannabis-based medications. Increased understanding of the endocannabinoid system sparked further scientific research and led to the realization that cannabinoids impact a much wider range of physiological functions than previously realized. Specialty biotechnology companies soon blossomed and now these companies research and develop wide-ranging novel new drug candidates to improve and extend patients’ lives, creating unique medicines to treat multiple maladies and answer unmet medical needs. These pioneering biotech companies are committed to developing cannabis-based pharmaceuticals and nutraceuticals delivered with unparalleled safety and new-found efficacy. At the vanguard of this surge in cannabinoid therapeutics, Earth Science Tech, Inc. (OTC: ETST) (ETST Profile) has taken another major step in its mission to become a global leader in the research, development and sale of hemp-derived, CBDbased pharmaceuticals, nutraceuticals and dietary supplements. The company’s recent decision to uplist on the OTCQB exchange will likely increase visibility and liquidity, and its comprehensive strategy of scientific development combined with robust retail creates a unique opportunity in the burgeoning medical cannabis markets. Other companies vying for position in these lucrative markets include CV Sciences, Inc. (OTC: CVSI), Axim Biotechnologies, Inc. (OTC: AXIM), GB Sciences, Inc. (OTC: GBLX) and Vitality Biopharma (OTC: VBIO).

To view an infographic of this editorial, click here.

Massive Markets

Little wonder that cannabis biotech companies are operating at full throttle. The global medical marijuana market is anticipated to exceed $55 billion by 2025 and, to meet increasing consumer demand, hemp-based nutraceuticals are rapidly gaining significant traction in a global nutraceuticals market projected to surpass $319 billion within the next five years. These eye-popping projections bode well for diversified cannabis biotech companies. CBD pharmaceuticals and nutraceuticals are the fastest growing sectors in the legal cannabis markets and the sector itself is among the fastest growing in all the markets. With multiple clinical research studies suggesting that CBD based pharmaceuticals and nutraceuticals have the potential to treat arthritis, MS, chronic pain, depression, epilepsy and a myriad of other illnesses and maladies, the prodigious market projections might even be underestimated.

Another Milestone

Seizing on the immense market opportunity and validating efficacy through scientific processes, Earth Science Tech, Inc. (OTC: ETST) is intent on becoming a global leader in the research, development and sale of hemp-derived, CBD-based pharmaceuticals, nutraceuticals and dietary supplements.  The company has racked up a succession of achievements since inception and its latest announcement establishes another milestone in its march toward global recognition. The company just issued a press release confirming that the U.S. Securities and Exchange Commission (SEC) approved the company’s Form 10 Registration Statement and Earth Sciences has officially up-listed to an OTCQB fully reporting company as of Sept. 10. The higher standards of the OTCQB markets provide a strong baseline for transparency, as well as the technology and regulations to enhance both access to information and trading experiences for investors. “Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness. We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders,” stated ETST’s President, Director and Chairman Nickolas S. Tabraue.

Eyes on the Prize

Grounded in science, ETST still understands that sales are essential for continued success. Earth Science aggressively markets and sells the highest-available quality and purity full spectrum hemp oil containing CBD. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, where the cannabinoids are kept at the rawest state possible to maintain essential therapeutic properties. Earth Science’s CBD products are marketed through multiple venues including a national group of independent distributors representing grocery and convenience stores, a national association of buying groups and trade organizations reaching up to 90,000 retail outlets, health food giant Karmavore Superfoods, international supplement distributor Forzagen, innumerable vape and e-liquid smoke shops, and online.

The company has four distinct, wholly owned subsidiaries:

  • Cannabis Therapeutics, Inc., (CTI) is developing an array of cannabinoid-based pharmaceuticals and nutraceuticals.
  • Kannabidioid, Inc., manufactures and distributes vapes/e-liquids and gummy edibles to vape and smoke shops.
  • Earth Science Pharmaceutical, Inc., (ESP) manufactures low-cost medical devices and vaccines for protection against sexually-transmitted infections.
  • Earth Science Foundation, Inc., a nonprofit organization formed to accept grants and donations to conduct further studies and help donate CBD products to those in need.

Cannabis Therapeutics is deeply invested in research and development to explore and harness the medicinal power of cannabidiol. Over 113 cannabinoids have been isolated from the cannabis plant, many obscure and only in trace amounts, but CBD, for which Cannabis Therapeutics has a provisional application patent, is the most promising of all. CTI’s mission is to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products using Earth Science Tech’s existing cannabis CBD patent and IP, as well as expected future technologies.

The company recently updated its report on research progress on two new cannabinoid-based pharmaceutical drugs, which are unique CBD formulated products – a neuron protector and a breast protector. Earlier studies by DV Biologics, a leading biological company, confirmed ETST high-grade hemp CBD oil deterred the formation of reactive oxygen species and cell death in human brain cells in vitro and may serve as a neuroprotectant to mitigate neurodegenerative disorders such as Alzheimer’s and Parkinson’s. With strong initial evidence that CBD contains anti-breast cancer properties, Earth Sciences also launched the development of proprietary prophylactic therapies to prevent breast cancer, and a treatment to help women with aggressive breast cancer. The company is very bullish on these CBD formulas.

The R&D work in progress at the prestigious laboratory, Centre De Développement Bioalimentaire Du Québec (CDBQ), has been exceptionally promising. CDBQ is highly experienced and able to utilize the most effective and economical solutions to develop products with the best efficacy and price-to-quality-to-market ratios. CDBQ is meticulously finalizing formulations that will include natural protective agents to assure long shelf life of the CBD formula.

The third CBD formula is a revolutionary superfood with unique organoleptic properties never seen on the market. Formulated from a mix of hemp oil and other vegetal oils, and enriched with a highly potent antioxidant, this product is designed to improve antioxidant ingestion. Earth Science developed this novel formula in collaboration with experts that successfully developed multiple products for some of the largest players in the food industry.

Not a One-trick Pony

Earth Science’s up-listing announcement is only the latest in a succession of successful advancements the company has made since its genesis. Last year’s achievements verify that.  In addition to talented and experienced leadership, the company’s success lies in the broad diversification of products, joint ventures, IPs and initiatives. Beyond the company’s multiple CBD-based initiatives and ventures, Earth Science’s medical device subsidiary Earth Science Pharmaceutical is making significant strides in the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Others Vying for Position

CV Sciences, Inc. (OTC: CVSI) focuses on the drug development, marketing and sale of products containing cannabidiol as the active pharmaceutical ingredient, and is engaged in the sale of CBD as well. The company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division centered in the manufacturing, marketing and sale of plant-based CBD products to a range of market sectors.

Axim Biotechnologies, Inc. (OTC: AXIM) researches, develops and produces cannabis-based pharmaceutical, nutraceutical and cosmetic products. The company has several products developed or in developmental stage for the treatment and/or prevention of multiple conditions and symptoms. Axim’s flagship products include a CBD-based, controlled-release chewing gum, another gum containing 50 mg of CBD undergoing clinical trials in patients with irritable bowel syndrome, and a combination CBD/tetrahydrocannabinol (THC) gum that will undergo clinical trials for the treatment of pain and spasticity associated with MS.

GB Sciences, Inc. (OTC: GBLX) is a diverse cannabis company focused on standardized cultivation and production methods, as well as biopharmaceutical research and development. The company’s goal is to create safe, standardized, pharmaceutical-grade cannabinoid therapies that target a variety of medical conditions. Company growth strategy is two-pronged — biomedical research for the development of cannabis-based therapies and the recreational market for cannabis in Nevada.

Vitality Biopharma (OTC: VBIO) is focused on the use of cannabinoids for the treatment of serious neurological and inflammatory disorders. The company has developed cannabinoid prodrugs, known as cannabosides, which upon ingestion may enable selective delivery of THC and CBD to the gastrointestinal tract. Vitality has filed intellectual property applications and is seeking global patent protection for prodrugs of THC, CB, and CBDV, as well as for its proprietary prodrug biosynthesis platform utilizing enzymatic glycosylation.

The Takeaway

As the list of curative applications continues to grow, there’s no longer any doubt about the therapeutic efficacy of cannabidiol. Employing that same certitude for impending CBD market growth has the potential to create a profit bonanza in strategically positioned portfolios.

For more information on Earth Science Tech, visit Earth Science Tech, Inc. (OTC: ETST)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.